Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.01M | $1.27M | $1.95M | $3.47M | $5.23M | $1.84M | $0.00 | — | — | — |
| Revenue growth | — | 26.1% | 53.1% | 77.6% | 51.0% | -64.8% | -100.0% | — | — | — |
| Operating income | -$39.9M | -$34.7M | -$1.68M | -$8.27M | -$7.79M | -$12.8M | -$31.8M | -$12.9M | -$5.73M | -$12.6M |
| Operating margin | -3946.5% | -2724.6% | -86.3% | -238.5% | -148.8% | -696.3% | — | — | — | — |
| Net income | -$39.5M | -$34.4M | -$1.67M | -$6.94M | -$7.35M | -$12.8M | -$31.6M | -$12.5M | -$5.58M | -$12.5M |
| Net margin | -3907.6% | -2701.7% | -85.6% | -200.2% | -140.5% | -693.8% | — | — | — | — |
| EPS (diluted) | -$2.43 | -$1.99 | -$1.16 | -$2.12 | -$0.50 | -$7.72 | -$14.88 | -$30.74 | -$69.54 | -$129.10 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.1M | -$27.7M | $4.18M | -$11.6M | -$10.3M | -$10.2M | -$17.6M | -$12.8M | -$4.53M | -$4.83M |
| Capital expenditures | $559K | $113K | $0.00 | $0.00 | $2.60K | $0.00 | — | — | $0.00 | $577K |
| Free cash flow | -$32.6M | -$27.8M | $4.18M | -$11.6M | -$10.3M | -$10.2M | — | — | -$4.53M | -$5.40M |
| Dividends paid | — | — | $0.00 | $134K | $0.00 | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $22.5M | $19.2M | $3.23M | $3.74M | $11.1M | $29.2M | $12.1M | $5.90M | $2.43M | $10.7M |
| Total assets | $63.2M | $35.0M | $6.61M | $13.9M | $24.9M | $40.8M | $14.7M | $6.59M | $3.02M | $11.1M |
| Total liabilities | $3.90M | $5.89M | $7.88M | $3.31M | $2.77M | $2.11M | $4.27M | $1.30M | $1.51M | $5.17M |
| Shareholders' equity | $59.3M | -$2.90M | -$1.27M | $10.6M | $22.2M | $38.7M | $10.4M | $5.29M | $1.51M | $5.89M |
| Retained earnings | -$76.6M | -$111M | -$5.14M | -$12.1M | -$19.4M | -$32.2M | -$63.8M | -$76.3M | -$81.9M | -$94.4M |
| Shares (wtd avg diluted) | 16.8M | 17.8M | 2.03M | 4.51M | 15.6M | 1.65M | 2.12M | 408K | 80.2B | 97.0B |
Every figure is extracted from Decoy Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.